|
COPYRIGHT 2005 International Medical News Group
New benzodiazepine receptor agonists for chronic insomnia--zaleplon, zolpidem, and eszopiclone--have shown fewer adverse effects compared with other medications, but additional studies are needed to assess these drugs' long-term effectiveness, concluded members of an independent panel convened by the National Institutes of Health in Bethesda, Md.
Only eszopiclone (Lunesta) has been approved for the long-term treatment of insomnia; the other drugs are approved for up to 35 days of use.
Five benzodiazepines--estazolam, flurazepam, quazepam, temazepam, and triazolam--also are approved by the Food and Drug Administration to treat insomnia, but adverse events including dependence, daytime sleepiness, and...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
